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SObjective: Although platinum-based chemotherapy is widely used in malignant pleural mesothelioma, its mod-
est therapeutic effect warrants identification of enhancing agents. As with many cancers, the phosphatidylinositol
3-kinase/Akt pathway is often activated in malignant pleural mesothelioma and has been implicated in the tumor’s
aggressiveness. Sirolimus is a well-established inhibitor of the mammalian target of rapamycin. We sought to
determine whether combination treatment with sirolimus and cisplatin would enhance cell death in malignant
pleural mesothelioma.
Methods: Human malignant pleural mesothelioma cell lines were incubated with sirolimus or cisplatin alone or
in combination and assayed for cell viability. To characterize phosphorylation status after treatment, Akt and
downstream proteins of mammalian target of rapamycin pathway, p70 S6 kinase and 4E-BP1, were analyzed
by Western blot. Effect of combination treatment was also analyzed with extreme drug resistance assay in 12
human malignant pleural mesothelioma tumors with varying resistance to cisplatin.
Results: Individual malignant pleural mesothelioma cell lines exhibited a range of sensitivities to each drug with-
out correlation with subtype. Sirolimus and cisplatin significantly (P ¼ .029) increased cell death versus either
drug alone in 4 cell lines. Combined treatment caused dephosphorylation of Akt, 4E-BP1, and p70 S6 kinase.
Cell proliferation was significantly decreased in tumors subjected to sirolimus and cisplatin versus cisplatin or
sirolimus alone.
Conclusions: Sirolimus appears to enhance the cytotoxicity of cisplatin in malignant pleural mesothelioma cell
lines through the mammalian target of rapamycin pathway. These results provide a basis for the clinical evalua-
tion of combined sirolimus and cisplatin chemotherapy in malignant pleural mesothelioma. (J Thorac Cardiovasc
Surg 2010;139:1233-40)Malignant pleural mesothelioma (MPM) is a mesodermally
derived neoplastic disease that arises in the pleura and kills
through direct invasion of surrounding structures. It affects
approximately 3000 patients in the United States annually.1
There are 3 distinct histologic subtypes: epithelial, sarcoma-
toid, and biphasic (a mixed type that contains both an epithe-
lial and a sarcomatoid component).1,2 The pathogenesis of
MPM is not fully understood. A highly aggressive cancer,
MPM responds poorly to treatment with platinum-based
combination chemotherapy, with a median survival of up
to 12 months. Multimodality treatment with cytoreductive
surgery, followed by a combination of chemotherapy and
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The Journal of Thoracic and Carselect patients with early-stage disease.1 Although platinum-
based chemotherapy is widely used, it has a modest thera-
peutic effect, and the identification of new agents to enhance
its therapeutic effect is warranted.
Cisplatin is a DNA-damaging agent used to treat a wide
range of tumor types. Apoptosis is triggered when the dam-
age done by cisplatin becomes irreversible. The major limi-
tation of cisplatin is its narrow therapeutic window. At high
doses it becomes nephrotoxic and ototoxic, whereas at low
doses the affected DNA is capable of self-repair.3,4 Cisplatin
has been studied as a single agent in patients with diffuse
MPM and demonstrated an overall response rate of 14%
when given daily at a dose of 100 mg/m2.5 Cisplatin alone
was included as the control arm of 2 phase III trials of 2
novel agents: pemetrexed in combination with cisplatin6
and cisplatin in combination with raltitrexed.5,7 Combined
chemotherapeutic regimens consisting of cisplatin and
doxorubicin and of cisplatin and mitomycin have been
tested, and moderate antitumor activity was observed with
both regimens.8 Finally, Vogelzang and colleagues6 con-
ducted a phase III trial to determine whether combination
treatment with pemetrexed and cisplatin would improve sur-
vival relative to cisplatin alone. In that study, median sur-
vival was 12.1 months in the pemetrexed and cisplatin arm
versus 9.3 months in the control (cisplatin alone) arm. Betterdiovascular Surgery c Volume 139, Number 5 1233
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S12Abbreviations and Acronyms344E-BP1 ¼The Jeukaryotic translation initiation factor
4E binding protein 1Akt ¼ protein kinase B
DMSO ¼ dimethyl sulfoxide
MPM ¼ malignant pleural mesothelioma
mTOR ¼ mammalian target of rapamycin
RPMI ¼ Roswell Park Memorial Institute
mediumThr ¼ threonineunderstanding of the molecular mechanisms of MPM cell
growth and regulation would facilitate the identification of
new pharmacologic agents to boost the efficacy of plati-
num-based chemotherapy.
The protein kinase B (Akt) pathway and its substrates are
thought to play a crucial role in human cancer.9 Activation of
Akt triggers antiapoptotic mechanisms that positively influ-
ence nuclear factor kB transcription, which in turn increases
angiogenesis, telomerase activity, and tumor invasion, thus
antagonizing cell-cycle arrest.9 Akt is often activated in
both human and mouse malignant mesotheliomas. Targeting
this pathway pharmacologically has been shown to inhibit
MPM cell growth and to increase sensitivity to conventional
chemotherapeutic agents.10,11 Sirolimus (previously known
as rapamycin) is a known inhibitor of the mammalian target
of rapamycin (mTOR), an important protein kinase in one of
the Akt pathways.12,13 Sirolimus has therefore been sug-
gested for use as a chemotherapeutic sensitizer.14
Amacrolide produced by Streptomyces hygroscopicus, si-
rolimus has antifungal and immunosuppressant activities.
The literature on sirolimus has been reviewed by Vignot
and associates.15 Sirolimus causes dephosphorylation and in-
activation of p70 S6 kinase, which is phosphorylated and ac-
tivated by mTOR. After its own phosphorylation, p70 S6
kinase phosphorylates S6, which controls the translation of
messenger RNA. In addition, sirolimus treatment leads to
the dephosphorylation and inactivation of eukaryotic transla-
tion initiation factor 4E binding protein 1 (4E-BP1), thereby
promoting its binding to and inactivation of eukaryotic trans-
lation initiation factor 4E. The latter inactivation blocks pro-
tein synthesis, leading to cell-cycle arrest in the G1 phase.
15
The mechanism underlying mTOR-mediated enhancement
of chemosensitivity remains unclear; however, several stud-
ies have suggested that Akt activation, dephosphorylation of
4E-BP1, and decrease of free eukaryotic translation initiation
factor 4E may play an important role.16,17
Sirolimus analogs currently in clinical development are
CCI-779, RAD001 (oral formulation), and AP23573. Tox-
icity studies have proved these analogs to be safe for use
in humans and no adverse immunosuppressive effectsournal of Thoracic and Cardiovascular Surhave been observed.15 In this study, we demonstrate that
combined exposure to sirolimus and cisplatin significantly
increases cell death in MPM cell lines relative to either
drug alone. We characterize the phosphorylation statuses
of Akt, p70 S6 kinase, and 4E-BP1 after each treatment.
Finally, we show that cell growth is significantly inhibited
in human MPM tumors by sirolimus and cisplatin treatment
as relative to either cisplatin or sirolimus alone.MATERIALS AND METHODS
Cell lines
MPM cell lines MS257 (epithelial), MS924 (epithelial), MS428 (sarco-
matoid), andMS589 (biphasic) were provided by Jonathan A. Fletcher from
the Department of Pathology, Brigham and Women’s Hospital. MPM cell
line H2052 (epithelial) was provided by Raphael Bueno and Gavin J.
Gordon from the Division of Thoracic Surgery, Brigham and Women’s
Hospital.18 MPM cell line JMN1B (epithelial) was provided by Dr. James
Rheinwald, Department of Dermatology, Brigham and Women’s Hospi-
tal.19 All 6 cell lines were maintained in Roswell Park Memorial Institute
medium (RPMI) 1640 (Gibco, Carlsbad, Calif) supplemented with 15%
fetal bovine serum (HyClone, Logan, Utah), 100-U/mL penicillin, 100-mg/
mL streptomycin, 0.25-mg/mL amphotericin B (Gibco), and 2-mmol/L
glutamine (Gibco).
Photographs of the cells were taken with the Nikon Eclipse TE2000-S
microscope, the SPOT Insight QE camera (Diagnostic Instruments, Sterling
Heights, Mich), and the SPOT Advanced computer program. The 203 ob-
jective lens was used with a 103 eyepiece. In all experiments, cells were
seeded 24 hours before treatment. All of the experiments were repeated at
least 3 times.
Drugs
Sirolimus in dimethyl sulfoxide (DMSO) was purchased from EMD
(EMD Biosciences, Inc, San Diego, Calif). The drug was diluted in fresh
medium without serum before each experiment. Cisplatin (cis-diammine-
platinum[II] dichloride) was purchased from Sigma (Saint Louis, Mo).
The drug was diluted in medium without serum for the stock solution.
Proliferation Assay for Cisplatin Dose-Response
Curve
MPM cell lines were plated in 96-well tissue culture plates; 1700 to 2500
cells (depending on cell line) per well were cultured in RPMI 1640 contain-
ing 15% fetal bovine serum overnight. Cells were incubated for 24 hours
with cisplatin (range, 1–500 mmol/L) or without cisplatin (control). After
24 hours, cells were washed twice with RPMI 1640, and cell viability
was analyzedwith the CellTiter 96 aqueous nonradioactive cell proliferation
assay (Promega, Madison,Wis). Experiments were performed at 37C, with
4 wells for each concentration and each cell line. The average and SD were
calculated from 4wells. Experiments were performed in triplicate on at least
2 separate occasions. Results are expressed as number of viable cells relative
to control (untreated cells) for each cell line within an experiment. The rel-
ative number of viable control cells thus equals 1 for each cell line. The ac-
tive washout of drugs in all these experiments was selected to mimic the
washout of drug after a 1-hour chemotherapeutic intracavitary lavage in pa-
tients with MPM undergoing surgery.
Proliferation Assay for Sirolimus Dose-Response
Curve
Cells were seeded as described for cisplatin experiments. The sirolimus
experiments differed in three respects. (1) The concentration range for siro-
limus was 1 to 500 nmol/L (rather than 1–500 mmol/L). (2) A control with
DMSO concentration matched to the samples was used. (3) The drug wasgery c May 2010
FIGURE 1. Cisplatin dose-response curves in malignant pleural mesothe-
lioma cell lines. Effect of loss of cell viability detected with different doses
of cisplatin (1–500-mmol/L) in 6 malignant pleural mesothelioma cell lines.
Results represent mean of at least 3 experiments; bars represent SD.
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formed after washout and every 24 hours subsequently for a total of 96
hours. Drug washout was designated time zero.
Proliferation Assay for Cisplatin-Sirolimus
Combination Treatment Dose-Response Curve
Cells were seeded as described for cisplatin and sirolimus individual ex-
periments. Cells were incubated for 24 hours with 100-nmol/L sirolimus,
50-mmol/L cisplatin, and both drugs. A control with DMSO concentration
matched to the samples was used. After 24 hours, the cells were washed
twice with phosphate-buffered saline solution, and cell proliferation was re-
corded at 0, 24 and 48 hours. All other conditions were identical to the pre-
vious experiments. A 50-mmol/L concentration of cisplatin was used
because it was the lowest cisplatin concentration that still yielded significant
cell death (Figure 1), and a 100-nmol/L concentration of sirolimus was used
because that dose yielded the maximal response (Figure 2).
Antibodies and Western Blotting
H2052 andMS428 cell lines were cultured overnight in RPMI 1640 con-
taining 15% fetal bovine serum. Cells (1.3–1.73106 cells/flask) were incu-
bated for 24 hours with indicated concentrations of either 100-nmol/L
sirolimus, 50-mmol/L cisplatin, or both drugs. Cells that were treated with
matched DMSO concentration served as the control preparation. After 24
hours, cells were washed twice with phosphate-buffered saline solution and
incubated with medium for an additional 24 hours. Cells were then lysed in
lysis buffer (50-mmol/L tris[hydroxymethyl]aminomethane chloride pH
8.0, 100-mmol/L sodium fluoride, 30-mmol/L sodium pyrophosphate,
2-mmol/L sodium molybdate, 5-mmol/L ethylenediaminetetraacetic acid,
2-mmol/L sodium vanadate, and 1% Tergitol-type NP-40) containing prote-
ase inhibitor cocktail (Sigma). Proteins were separated by gel electrophoresis
on 4% to 12% tris(hydroxymethyl)aminomethane/glycine polyacrylamide
gels (Invitrogen, Carlsbad, Calif), transferred to nitrocellulose membranes
(Bio-Rad, Hercules, Calif), and detected by immunoblotting with an en-
hanced chemiluminescence system (Boston Bioproducts, Worcester, Mass).
Antibodies for phosphorylated 4E-BP1 threonine (Thr) 70, phosphorylated
4E-BP1Thr 37/46, phosphorylated 70S6kinaseThr 389, andphosphorylated
Akt Thr 308 were purchased from Cell Signaling Technology (Beverly,
Mass). Glyceraldehyde 3-phosphate dehydrogenase antibody was purchased
from Ambion (Austin, Tex). ECL anti–rabbit IgG horseradish peroxidase–
linked species-specificwhole antibody and ECL anti–mouse IgG horseradish
peroxidase–linked species-specific whole antibody were purchased from
Amersham Bioscience (GE Healthcare, Piscataway, NJ). The protein levels
were studied 24 hours (as a middle time window between 0–48 hours) after
the drugs were washed out because for MS428 the strongest effect of the cis-
platin and sirolimus treatment was observed after 48 hours.
Extreme Drug Resistance Assay
Under an institutional review board–approved protocol, 12 tumor spec-
imens removed during cytoreductive surgery for MPM were analyzed for
extreme drug resistance and intermediate resistance in a cellular prolifera-
tion assay described previously.20,21
Statistical Analysis
Each dose-response curve was characterized by a 4-parameter logistic
model estimated by nonlinear regression analysis with GraphPad Prism 4
software (GraphPad Software, Inc, San Diego, Calif). In the absence of
treatment with cisplatin or sirolimus, the control dose was set arbitrarily 2
logs below the lowest drug concentration, and control cell viability was
set to reflect 100% normal proliferation. Nonlinear regression analysis
with log-transformed data was used to determine half maximal inhibitory
concentration (IC50) value (theoretical concentration required to inhibit
50% of cells) as a relative measure of drug sensitivity. The 2-sample t
test based on an assumption of unequal variances was used with theThe Journal of Thoracic and CarSatterthwaite approximation to compare the difference in loss of cell viabil-
ity between 2 treatment groups in each cell line. Representative experiments
typically correspond to the median of the outcome range among the repeated
experiments. Experiments were repeated 3 times. The differences in cell
growth inhibition in tumor specimens treated with cisplatin alone versus
the combination treatment were analyzed with a paired t test. The same anal-
ysis was performed for tumors treated with sirolimus alone versus the com-
bination treatment. All P values were based on a 2-sided hypothesis and
were computed by SAS 9.1 software (SAS Institute, Inc, Cary, NC).
RESULTS
Effect of Cisplatin on Cell Viability
The relationship between concentration of cisplatin
(range, 1–500 mmol/L) and loss of cell viability in MPM
cell lines (MS924, MS428, H2052, MS589, MS257, and
JMN1B) is depicted in Figure 1. The cell lines expressed
varying sensitivities to cisplatin, falling into 2 groups with
one relatively more sensitive than the other. Nonlinear re-
gression analysis of survival curves produced an excellent
fit for all cell lines (R2 ¼ 0.8725–0.9870) except for
H2052. Extrapolated IC50 values showed that 4 of the cell
lines (MS257, JMN1B, H2052, and MS589) were relatively
more sensitive to cisplatin (IC50 range, 21.06–97.79 mmol/
L) than were the other 2 (MS924 and MS428), which were
relatively more resistant to cisplatin. We could not reliably
calculate the IC50 values from this analysis, because the
curves ended very close to the 50% mark of relative cell
viability. The graph in Figure 1, however, shows that the IC50
of MS924 and MS428 was higher than the IC50 of MS589.
Effect of Sirolimus on Cell Viability
The relationship between sirolimus concentration (range,
1–500 nmol/L) and loss of cell viability is shown in Figure 2.
The data revealed that different cell lines have differentdiovascular Surgery c Volume 139, Number 5 1235
FIGURE 2. Sirolimus dose-response curves in malignant pleural mesothelioma cell lines. Effect of loss of cell viability detected with different doses of
sirolimus (1–500 nmol/L) and time courses in 6malignant pleural mesothelioma cell lines. Results represent mean of at least 3 experiments; bars represent SD.
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treatment was time dependent. Four of 6 cell lines responded
maximally 72 hours after the drug was washed out. At least
3 of 6 cell lines responded maximally to the 100-nmol/L
dose of sirolimus.Effect of Combined Treatment With Sirolimus and
Cisplatin on Cell Viability
The effect of combination treatment with 100-nmol/L
sirolimus and 50-mmol/L cisplatin is depicted in Figure 3.
This effect was stronger than that of either sirolimus or cis-
platin treatment alone. Figure 3 summarizes the data derived
from the 3 test conditions (plus control) across all cell lines:
sirolimus alone, cisplatin alone, and combined sirolimus and
cisplatin. The MS589 and MS428 cell lines demonstrated
91.2% (P< .0001) and 45.1% (P ¼ .0002) losses of cell
viability, respectively, with combined sirolimus and cis-
platin and with cisplatin alone 48 hours after the drugs
were washed out. JMN1B and MS924 demonstrated
46.6% (P ¼ .0010) and 34.9% (P ¼ .0009) reductions in
cell viability, respectively, with combined treatment and
with cisplatin alone at time zero. Loss of cell viability with
combined treatment in the MS257 and H2052 cell lines1236 The Journal of Thoracic and Cardiovascular Surdid not reach statistical significance relative to values for cis-
platin alone. Those cell lines demonstrated relatively high
sensitivity to cisplatin alone (Figure 1).Effects of Sirolimus, Cisplatin, and Combined
Sirolimus and Cisplatin on Akt and Proteins
Downstream to mTOR
We sought to determine whether Akt and downstream pro-
teins of mTOR were modulated by treatment with sirolimus,
cisplatin, and the combined regimen. First, withWestern blot
analysis, we analyzed phosphorylation status after each treat-
ment in 2 cell lines (MS428 and H2052) that demonstrated
reciprocal sensitivity to each drug.Aktwas dephosphorylated
at Thr 308 by cisplatin alone and the combined sirolimus and
cisplatin treatment in both cell lines (Figure 4); however, siro-
limus alone increased the phosphorylation of Akt Thr 308 rel-
ative to the control cells. Both cell lines (Figure 4) exhibited
high p70 S6 kinase dephosphorylation at Thr 389 both with
sirolimus alone and with sirolimus and cisplatin together.
Phosphorylation of p70 S6 kinase at Thr 389 was observed
both in the control preparation and with cisplatin treatment
alone, indicating that cisplatin does not affect the phosphory-
lation of this kinase.gery c May 2010
FIGURE 3. Sirolimus and cisplatin combination in malignant pleural mesothelioma cell lines. A, Effects of loss of cell viability in different malignant pleural
mesothelioma cell lines (MS589, MS428, JMN1B, and MS924) with sirolimus (RAP), cisplatin (CIS), combination of both drugs (RAPþCIS), and nontreat-
ment control (CT) of dimethyl sulfoxide vehicle. For each cell line, enlarged figure near each graph shows increased loss of cell viability from both drugs
versus cisplatin alone at specific time points. Columns represent mean of 4 wells; bars represent SD. Each P value is presented in box. B, Malignant pleural
mesothelioma cell lines MS428, MS924, and H2052 were treated as in part A and photographed 24 hours after drugs were washed out. Original magnification
2003; abbreviations as in part A.
The Journal of Thoracic and Cardiovascular Surgery c Volume 139, Number 5 1237
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FIGURE 4. Dephosphorylation of Akt, p70 S6 kinase, and 4E-BP1 after sirolimus and cisplatin combined treatment. Western blot analysis demonstrates
phosphorylation status of the Akt/mTOR pathway proteins using specific antibodies (Phospho) against specific phosphorylation sites (I-IV) of the indicated
proteins. Column A represents malignant pleural mesothelioma cell line MS428. Column B represents malignant pleural mesothelioma cell line H2052. Both
cell lines were treated with sirolimus (R), cisplatin (C), and the combination of both drugs (RþC).Untreated cells in vehicle (dimethyl sulfoxide) were used as
control (CT). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as loading control.
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ylation of 4E-BP1 at Thr 70 with both sirolimus alone and
cisplatin alone but showed virtually complete dephosphory-
lation of 4E-BP1 with combined sirolimus and cisplatin. We
observed a different pattern of phosphorylation with a differ-
ent phosphorylated 4E-BP1 antibody targeted to phosphory-
lation site Thr 37/46. MS428 (Figure 4) exhibited slight
dephosphorylation after treatment both with sirolimus alone
and with cisplatin alone, whereas slightly greater dephos-
phorylation was observed with sirolimus and cisplatin com-
bined. H2052 produced similar results in terms of sirolimus
treatment with the same antibody to Thr 37/46 (Figure 4);
however, we observed significant dephosphorylation of
4E-BP1 with cisplatin alone and with both drugs relative to
MS428 under the same conditions.
Effect of Combined Treatment With Sirolimus and
Cisplatin on Mesothelioma Tumor Specimens
To obtain a clearer indication of the efficacy of the siroli-
mus and cisplatin combination, we tested 12 tumor speci-1238 The Journal of Thoracic and Cardiovascular Surmens with the cellular proliferation assay (extreme drug
resistance assay). Tumor specimens exhibiting varying re-
sistances to cisplatin were treated with combined sirolimus
and cisplatin and compared with cisplatin alone. Percentage
cell growth inhibition was significantly higher when the 12
tumor specimens were exposed to the sirolimus and cisplatin
combination compared to cisplatin alone (P¼ .0002; Table 1)
A similar increase in cell growth inhibition was observed
with the sirolimus and cisplatin combination compared
with sirolimus alone (P ¼ .0133; Table 1).
DISCUSSION
In these experiments, combined treatment with sirolimus
and cisplatin elicited greater cell death in MPM cell lines
than did either drug alone. Combined treatment caused
greater dephosphorylation of 4E-BP1 than did either drug
alone and caused dephosphorylation of Akt and p70 S6
kinase. Finally, in 12 MPM tumor specimens, we demon-
strated that cell growth inhibition is greater after combined
sirolimus and cisplatin treatment than after either drug alone.gery c May 2010
TABLE 1. Inhibition by cellular proliferation assay after each
treatment
Cisplatin Sirolimus
No. of specimens 12 12
Average percent inhibition
after single-drug treatment
(average and range)
61% (34%–87%) 64% (1%–90%)
Average percent inhibition
after combined therapy
(average and range)
84% (68%–98%) 84% (68%–98%)
Average increase in
percent inhibition with
combination (average
and range)
23% (2%–44%) 20% (6%–74%)
P value* .0002 .0133
*The t test was performed to compare inhibition between single-drug treatment
and combined therapy.
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vealed varying sensitivities, a finding that has been shown
previously by Gordon and colleagues,18 and there was no
correlation between drug sensitivity and cell type. Interest-
ingly, at least in 3 of 6 cell lines, cisplatin sensitivity was in-
versely related to sirolimus sensitivity. For at least 3 of the
cell lines, the maximum effect was achieved at the 100-
nmol/L dose of sirolimus. Sawyers22 has suggested that if
more than 1-nmol/L of sirolimus is required to achieve the
desired cell effect, then it is likely that other pathways in ad-
dition to mTOR are probably involved, which justifies the
use of the combined regimen in our study.
In our study, the combination sirolimus and cisplatin sig-
nificantly increased cell death in 4 MPM cell lines compared
with either drug alone. For 2 cell lines (MS428 and MS589),
this effect was time dependent.
Sirolimus inhibits mTOR, induces insulin receptor sub-
strate 1 expression, and abrogates feedback inhibition of
the pathway, resulting in Akt activation.23 We also observed
Akt activation in 2 MPM cell lines treated with sirolimus.
Cisplatin alone or combined with sirolimus resulted in
dephosphorylation of Akt.
Sirolimus leads to dephosphorylation and inactivation of
p70 S6 kinase.15 In our study, cell lines MS428 and
H2052 when treated with sirolimus alone or combined siro-
limus and cisplatin, displayed dephosphorylation of p70 S6
kinase.
Our work with the MS428 and H2052 cell lines subjected
to sirolimus treatment shows that the 4E-BP1 Thr 37/46 site
is less sensitive to sirolimus, whereas Thr 70 is highly sen-
sitive to sirolimus, as reported by others.24 Dephosphoryla-
tion of 4E-BP1 (Thr 70 in both cell lines and Thr 37/46 in
MS 428 cell line) after combination treatment with cisplatin
and sirolimus was greater than with either drug alone. Cis-
platin treatment also moderately dephosphorylated 4E-BP1
at Thr 70 in both cell lines, but the dephosphorylation effectThe Journal of Thoracic and Carat Thr 37/46 was strong only in the H2052 cell line. Whether
sensitivity to cisplatin correlates with the ability of Thr 37/46
to be dephosphorylated merits further study.
Preliminary results of the cellular proliferation assay in 12
MPM tumor specimens support our in vitro findings. In the
tumor specimens, exposure to combined sirolimus and cis-
platin significantly increased the inhibition of cell growth
relative to cisplatin alone or sirolimus alone. Of interest,
the increase in cell growth inhibition with the combination
treatment is significant over a range of sensitivity to cisplatin
alone. These data provide additional support for the siroli-
mus and cisplatin combination in the treatment of MPM.
Other in vitro studies of sirolimus and cisplatin in different
types of cancer have shown that sirolimus enhances cell death
and increases sensitivity to cisplatin.3,14 The mechanism by
which sirolimus increases the sensitivity of cisplatin is not
clear; however, several reports have highlighted the involve-
ment of different pathways. It is important to note that these
analyses have been performed on different cell lines, at differ-
ent concentrations of cisplatin and sirolimus, and with differ-
ent sirolimus derivates, and all these factorsmay influence the
results. Yan and coworkers17 have reported that activation of
Akt and dephosphorylation of 4E-BP1, with attendant de-
crease in free eukaryotic translation initiation factor 4E levels
and cap-dependent translation, mediates the proapoptotic
effect of sirolimus. Therefore, eukaryotic translation initiation
factor 4E is a key factor in promoting tumorigenic activity and
antiapoptotic activity.16 Our data revealed similar effects of
complete dephosphorylation of 4E-BP1 Thr 70with the com-
bined regimen relative to either drug alone. From our results,
it appears that inhibition of p70 S6 kinase may be involved in
the sirolimus chemosensitivity mechanism. In addition, the
function of S6 kinase, which is downstream to p70 S6 kinase,
has been related to apoptotic resistance of mesothelioma cells
in 3-dimensional culture and tumor fragment spheroids.25
Further investigation will be required to elucidate other path-
ways that are involved in the molecular mechanism of this
combination of drugs in MPM cell lines.
To our knowledge, this is the first demonstration of the
effect of combined sirolimus and cisplatin chemotherapy on
human MPM cell lines and tumor specimens. The enhanced
cytotoxic effect of the combined regimen relative to either
drug alone has important clinical implications when one
considers the current limitations of cisplatin chemotherapy.
The dephosphorylation effect of combined treatment on Akt,
4E-BP1, and P70 S6 kinase supports the hypothesis that si-
rolimus increases cisplatin cytotoxicity through the mTOR
pathway. Our views are further supported by the inhibitory
effect of this treatment on cell growth in human MPM tu-
mors, as evidenced by cellular proliferation assay (extreme
drug resistance). In our view, the effects of the sirolimus
and cisplatin combination demonstrated in this study pro-
vide ample justification for pursuing this treatment in the
clinical setting of trimodality therapy for MPM.diovascular Surgery c Volume 139, Number 5 1239
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